Overview and Scope
The stool softener market consists of sales of docusate sodium, docusate calcium, liquid gels, and fiber supplements. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
Sizing and Forecast
The stool softener market size has grown strongly in recent years. It will grow from $1.58 billion in 2023 to $1.69 billion in 2024 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to the aging population, dietary changes, increased public awareness about digestive health, increased surgical procedures, and lack of physical activity.
The stool softener market size is expected to see strong growth in the next few years. It will grow to $2.26 billion in 2028 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to increasing cases of gastrointestinal conditions, higher healthcare spending, increasing marketing efforts by pharmaceutical companies, the shift of many stool softeners from prescription-only to over-the-counter status, and chronic disease prevalence. Major trends in the forecast period include improvements in medical diagnostics and treatments, the development and approval of more effective stool softener formulations, innovations in formulation technology, the development of personalized stool softener products, and the development of effervescent stool softener tablets.
Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/stool-softener-global-market-report
Segmentation & Regional Insights
The stool softener market covered in this report is segmented –
1) By Type: Liquid, Softgel Capsule
2) By Form: Medicines, Procedures
3) By Mode Of Administration: Oral, Rectal
4) By Availability: Over-The-Counter, Prescription
5) By End Use: Hospitals, Clinics, Home Care, Other End Uses
North America was the largest region in the stool softener market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the stool softener market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16548&type=smp
Major Driver Impacting Market Growth
The increasing prevalence of gastrointestinal disorders is expected to propel the growth of the stool softener market going forward. Gastrointestinal disorders refer to any condition or disease that affects the gastrointestinal tract, which includes the mouth, esophagus, stomach, small intestine, large intestine, and anus. The increasing prevalence of gastrointestinal disorders is attributed to various factors, including lifestyle changes such as poor diet, lack of exercise, and stress. Stool softeners help alleviate gastrointestinal disorders by making stools easier to pass, thereby preventing constipation and reducing strain during bowel movements. For instance, in 2023, according to Crohn’s and Colitis Canada, a Canada-based non-profit organization, the number of people in Canada with IBD is increasing rapidly, from 322,600 in 2023 (0.8% of the population) to 470,000 in 2035 (1.1% of the population). In 2023, 11,000 people will be diagnosed (1 every 48 minutes), and by 2035, this will rise to 14,000 (1 every 38 minutes). Therefore, the increasing prevalence of gastrointestinal disorders is driving the growth of the stool softener market.
Key Industry Players
Major companies operating in the stool softener market are F. Hoffmann-La Roche Ltd., Bayer AG, AstraZeneca Plc., Abbott Laboratories Inc., Takeda Pharmaceutical Company Ltd., GlaxoSmithKline Plc, Boehringer noteIngelheim GmbH, Solvay S.A., Teva Pharmaceutical Industries Ltd., Mylan N.V., Purdue Pharma L.P., Mallinckrodt Plc, Aristo Pharma GmbH, Raptakos Brett Co. Ltd., Unipex Group Inc., Chemo Biological, Angiolife Healthcare Pvt. Ltd., Iscon Life Sciences, Starmed Pvt. Ltd., Phaedrus Ltd., Stadmed Pvt. Ltd., Avrio Health L.P., Healwell, Velnex Medicare, Sanify Healthcare Pvt. Ltd.
The stool softener market report table of contents includes:
1. Executive Summary
2. Stool Softener Market Characteristics
3. Stool Softener Market Trends And Strategies
4. Stool Softener Market – Macro Economic Scenario
5. Global Stool Softener Market Size and Growth
.
.
.
32. Global Stool Softener Market Competitive Benchmarking
33. Global Stool Softener Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Stool Softener Market
35. Stool Softener Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
